In phase 3, the KATHERINE trial explored the application of adjuvant T‐DM1 compared with trastuzumab for HER2‐positive early breast cancer patients with residual invasive disease after the administration of neoadjuvant chemotherapy and HER2‐targeted therapy. This evidence concerns the gene ERBB2 and breast carcinoma.